First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak

Pediatrics

Volumn 135, Issue 5, 2015, Pages 798-804

  McNamara, Lucy A ^a,b   Shumate, Alice M ^a,c   Johnsen, Peter ^d   MacNeil, Jessica R ^b   Patel, Manisha ^b   Bhavsar, Tina ^e   Cohn, Amanda C ^b   Dinitz Sklar, Jill ^c,f   Duffy, Jonathan ^g   Finnie, Janet ^d   Garon, Denise ^c   Hary, Robert ^h   Hu, Fang ^b   Kamiya, Hajime ^a,b   Kim, Hye Joo ^e   Kolligian, John ^d   Neglia, Janet ^d   Oakley, Judith ^d   Wagner, Jacqueline ^d   Wagner, Kathy ^d   Wang, Xin ^b   Yu, Yon ^e   Montana, Barbara ^c   Tan, Christina ^c   Izzo, Robin ^d   Clark, Thomas A ^b   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^d PRINCETON UNIVERSITY   (United States)

^e Office of the Department   (United States)

^f Mercer County Division of Public Health   (United States)

^g NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^h Princeton Health Data   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; BACTERIAL ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; DOSE RESPONSE; EPIDEMIC; FEMALE; FEVER; HEADACHE; HUMAN; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; POPULATION RISK; PRIORITY JOURNAL; RASH; RHABDOMYOLYSIS; SEROGROUP B MENINGOCOCCAL DISEASE; UNITED STATES; UNIVERSITY; UNIVERSITY STUDENT; UNSTRUCTURED INTERVIEW; VACCINATION; VACCINATION COVERAGE; MENINGOCOCCAL INFECTIONS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, BACTERIAL; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; UNITED STATES; UNIVERSITIES; YOUNG ADULT;

EID: 84929484046     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-4015     Document Type: Article

References (22)

1. Cohn AC, MacNeil JR, Clark TA, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1-28
2. Dolan Thomas J, Hatcher CP, Satterfield DA, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS ONE. 2011;6(5):e19361
3. Mothershed EA, Sacchi CT, Whitney AM, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol. 2004;42(1): 320-328
4. Wang X, Theodore MJ, Mair R, et al. Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens. J Clin Microbiol. 2012;50(3):702-708
5. Maiden MCJ, Bygraves JA, Feil E, et al. Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998;95(6):3140-3145
6. Popovic T, Schmink S, Rosenstein NA, et al. Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by Neisseria meningitidis serogroup C. J Clin Microbiol. 2001;39(1):75-85
7. Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis. 2000;182(4):1169-1176
8. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29 (29-30):4739-4744
9. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45): 19490-19495
10. Giuliani MM, Biolchi A, Serruto D, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine. 2010;28(31):5023-5030
11. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA. 1995;273(5): 383-389
12. Centers for Disease Control and Prevention. Meningococcal disease and college students: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-7):13-20
13. Curtis CR, Yankey D, Jeyarajah J, et al; Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012. MMWR Morb Mortal Wkly Rep. 2013; 62(34):685-693
14. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191
15. Climent Y, Yero D, Martinez I, et al. Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba. J Clin Microbiol. 2010;48(3):802-810
16. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286(6):688-693
17. Froeschle JE. Meningococcal disease in college students. Clin Infect Dis. 1999; 29(1):215-216
18. Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. JAMA. 1999; 281(20):1906-1910
19. Neal KR, Nguyen-Van-Tam J, Monk P, O'Brien SJ, Stuart J, Ramsay M. Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodation. Epidemiol Infect. 1999;122(3):351-357
20. Santolaya ME, O'Ryan M, Valenzuela MT, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013;9(11):2304-2310
21. Santolaya ME, O'Ryan ML, Valenzuela MT, et al; V72P10 Meningococcal B Adolescent Vaccine Study Group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: A phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012; 379(9816):617-624
22. Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observerblind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123-2131